Remove 2019 Remove Communication Remove Diabetes
article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

Diabetes 101
article thumbnail

Reach 35 New Countries and Improve Diabetes Care Communication: Viseven Collaborations

Viseven

In February 2019, Viseven, a global provider of digital solutions for the life sciences industry, announced a strategic collaboration with a global pharmaceutical company. This company specializes in biopharmaceuticals, diabetes care, obesity care, and other severe chronic diseases. Let us know!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: The new weight loss drugs are revolutionizing our understanding of desire. Food cravings could be just the beginning

STAT

were prescribed a GLP-1 agonist in 2022, up from about 230,000 in 2019, according to a recent analysis by data insights company Komodo Health. Around Thanksgiving 2021, Fernandez’s doctor approached him about trying something different: a new weight loss drug called Wegovy.

article thumbnail

How to Improve Communication between Patient and Doctor?

Viseven

Imagine this as a patient when you are under extreme duress and walk into a clinic or hospital; clear communication is often not feasible. Compelling and well-enunciated communications are quite rare between patient and doctor. Importance of Quality Patient-Doctor Communication.

article thumbnail

How the patient voice is becoming vital for drug approval

pharmaphorum

This can lead to metabolic abnormalities including insulin resistance, diabetes, and elevated levels of blood lipids (such as high cholesterol). Before being approved, metreleptin had gone through two previous owners, and had been rejected for funding on the grounds of inadequate evidence in 2019. Fighting for access.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. The Health Survey for England 2019 reported that 28% of adults in the UK were obese and 36.2% In the first quarter since its launch as an approved therapy for type 2 diabetes, Mounjaro has proven to be a lucrative drug, making $97.3 were overweight but not obese.

article thumbnail

First results of the DiabetRisk study

pharmaphorum

First results of the DiabetRisk study – Over 8% of patients identified with undiagnosed diabetes or pre-diabetes at dental practices. The DiabetRisk study could contribute to early diagnosis of diabetes in thousands of dental patients each year – and in every country worldwide.